Concepedia

Author

Luz Hammershaimb

National Cancer Institute

Also Known As

L Hammershaimb, L. D. Hammershaimb, L. Hammershaimb, Luz D. Hammershaimb, M.D., Luz Hammershaimb

31

Publications

2.4K

Citations

13

H-Index

21

Concepts

All Affiliations

National Cancer InstituteUniversity of PittsburghUPMC Hillman Cancer CenterRadboud University Medical CenterOregon Health & Science University
LH

About

Luz Hammershaimb is an author at National Cancer Institute specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

410

2

Pharmacology

5

5

246

3

Immunology

4

4

290

4

Pathology

3

3

45

5

Health Sciences

2

2

64

Luz Hammershaimb

×

16

Publications

2.3K

Citations

13

H-Index

YearCitations

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

Frank V. Fossella, Russell F. DeVore, Ronald N. Kerr,

Journal of Clinical Oncology

2000

1.4K

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin α<sub>v</sub>β<sub>3</sub>, ± dacarbazine in patients with stage IV metastatic melanoma

Peter Hersey, Jeffrey A. Sosman, Steven O’Day,

Cancer

2010

186

Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

Douglas G. McNeel, Jens C. Eickhoff, Fred T. Lee,

Clinical Cancer Research

2005

157

Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group.

F. Moffat, Carl Pinsky, Luz Hammershaimb,

Journal of Clinical Oncology

1996

126

Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors

Catherine Delbaldo, Éric Raymond, Karina Vera,

Investigational New Drugs

2007

100

Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.

René Bruno, Robert Olivares, J. Bérille,

PubMed

2003

84

EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies

Deirdre O’Mahony, John C. Morris, Maryalice Stetler‐Stevenson,

Clinical Cancer Research

2009

58

Use of Carcinoembryonic Antigen Radioimmunodetection and Computed Tomography for Predicting the Resectability of Recurrent Colorectal Cancer

Kevin S. Hughes, Carl Pinsky, Nicholas J. Petrelli,

Annals of Surgery

1997

55

A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC)

Chandra P. Belani, Joel Veas Rodríguez, Joachim von Pawel,

Lung Cancer

2000

54

Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study

Cornelis J.A. Punt, H.J. Keizer, J. Douma,

Annals of Oncology

2002

27

Page 1